Your browser doesn't support javascript.
loading
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Alsoud, Dahham; Moes, Dirk Jan A R; Wang, Zhigang; Soenen, Rani; Layegh, Zohra; Barclay, Murray; Mizuno, Tomoyuki; Minichmayr, Iris K; Keizer, Ron J; Wicha, Sebastian G; Wolbink, Gertjan; Lambert, Jo; Vermeire, Séverine; de Vries, Annick; Papamichael, Konstantinos; Padullés-Zamora, Núria; Dreesen, Erwin.
Afiliación
  • Alsoud D; Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
  • Moes DJAR; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.
  • Wang Z; Clinical Pharmacology and Pharmacotherapy Unit, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • Soenen R; Dermatology Research Unit, Ghent University, Ghent, Belgium.
  • Layegh Z; Department of Dermatology, Ghent University Hospital, Ghent, Belgium.
  • Barclay M; Department of Pathology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
  • Mizuno T; Departments of Gastroenterology and Clinical Pharmacology, Christchurch Hospital, Te Whatu Ora Waitaha and University of Otago, Christchurch, New Zealand.
  • Minichmayr IK; Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • Keizer RJ; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Wicha SG; Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria.
  • Wolbink G; InsightRX, San Francisco, California.
  • Lambert J; Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Hamburg, Germany.
  • Vermeire S; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center Location Reade, Amsterdam, Netherlands.
  • de Vries A; Sanquin Research and Landsteiner Laboratory, Department of Immunopathology, Amsterdam UMC, Amsterdam, Netherlands.
  • Papamichael K; Dermatology Research Unit, Ghent University, Ghent, Belgium.
  • Padullés-Zamora N; Department of Dermatology, Ghent University Hospital, Ghent, Belgium.
  • Dreesen E; Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
Ther Drug Monit ; 46(3): 291-308, 2024 Jun 01.
Article en En | MEDLINE | ID: mdl-38648666
ABSTRACT

BACKGROUND:

Infliximab, an anti-tumor necrosis factor monoclonal antibody, has revolutionized the pharmacological management of immune-mediated inflammatory diseases (IMIDs). This position statement critically reviews and examines existing data on therapeutic drug monitoring (TDM) of infliximab in patients with IMIDs. It provides a practical guide on implementing TDM in current clinical practices and outlines priority areas for future research.

METHODS:

The endorsing TDM of Biologics and Pharmacometrics Committees of the International Association of TDM and Clinical Toxicology collaborated to create this position statement.

RESULTS:

Accumulating data support the evidence for TDM of infliximab in the treatment of inflammatory bowel diseases, with limited investigation in other IMIDs. A universal approach to TDM may not fully realize the benefits of improving therapeutic outcomes. Patients at risk for increased infliximab clearance, particularly with a proactive strategy, stand to gain the most from TDM. Personalized exposure targets based on therapeutic goals, patient phenotype, and infliximab administration route are recommended. Rapid assays and home sampling strategies offer flexibility for point-of-care TDM. Ongoing studies on model-informed precision dosing in inflammatory bowel disease will help assess the additional value of precision dosing software tools. Patient education and empowerment, and electronic health record-integrated TDM solutions will facilitate routine TDM implementation. Although optimization of therapeutic effectiveness is a primary focus, the cost-reducing potential of TDM also merits consideration.

CONCLUSIONS:

Successful implementation of TDM for infliximab necessitates interdisciplinary collaboration among clinicians, hospital pharmacists, and (quantitative) clinical pharmacologists to ensure an efficient research trajectory.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Monitoreo de Drogas / Infliximab Límite: Humans Idioma: En Revista: Ther Drug Monit Año: 2024 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Monitoreo de Drogas / Infliximab Límite: Humans Idioma: En Revista: Ther Drug Monit Año: 2024 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Estados Unidos